Ionis Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.03.18	IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease (PR Newswire)
27.02.18	Ionis Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
20.02.18	Ionis Licences New Antisense Drug for Kidney Disease to AstraZeneca (PR Newswire)
13.02.18	Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call (PR Newswire)
31.01.18	Qualcomm and Samsung Announce Expanded Strategic Relationship (PR Newswire)
11.01.18	Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer (PR Newswire)
08.01.18	Ionis' Inotersen NDA Accepted for Priority Review by the FDA (PR Newswire)
21.12.17	Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal Disorders (PR Newswire)
20.12.17	EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours (RTTNews)
18.12.17	Ionis' License Agreement for Huntington's Disease Drug, IONIS-HTT Rx, Receives HSR Clearance (PR Newswire)
11.12.17	Roche lizensiert IONIS-HTT von Ionis Pharmaceuticals für 45 Mio USD ein (AWP) Roche hat den Wirkstoffkandidaten IONIS-HTT vom US-Biotechunternehmen Ionis Pharmaceuticals einlizensiert.» mehr
11.12.17	Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease (PR Newswire)
07.12.17	Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference (PR Newswire)
16.11.17	Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen (PR Newswire)
09.11.17	Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure (PR Newswire)
08.11.17	Ionis Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
07.11.17	Ionis Announces Management Transitions (PR Newswire)
07.11.17	Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017 (PR Newswire)
07.11.17	FDA Lifts Hold On CLLS' Trials, Double Delight For Roche, COLL Will Have To Wait (RTTNews)
06.11.17	Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA (PR Newswire)
03.11.17	Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency (PR Newswire)
02.11.17	Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting (PR Newswire)
01.11.17	Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting (PR Newswire)
27.10.17	Ionis and Biogen Win Prestigious Prix Galien Best Biotechnology Product Award for SPINRAZA (PR Newswire)
27.10.17	Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S. (PR Newswire)
25.10.17	ATOS Catches Eyes, PTIE Gains, CNCE Hits Right Notes, SMMT Keeps Sliding (RTTNews)
24.10.17	NuVasive Announces $100 Million Share Repurchase Program (PR Newswire)
24.10.17	Ionis Pharmaceuticals to Hold Third Quarter 2017 Financial Results Webcast (PR Newswire)
18.10.17	Ionis Enters into Collaboration with Seventh Sense Biosystems to Support Development of Improved Blood Collection and Diagnostic Device (PR Newswire)
15.10.17	Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress (PR Newswire)
13.10.17	Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease (PR Newswire)
11.09.17	New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi (PR Newswire)
05.09.17	Tailored Brands Provides Hurricane Harvey Relief (PR Newswire)
30.08.17	2018 Hyundai Sonata Earns 2017 IIHS TOP SAFETY PICK+ Award (PR Newswire)
30.08.17	Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen (PR Newswire)
24.08.17	Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation (PR Newswire)
23.08.17	Technical Snapshots for These Drug Makers Stocks -- Teva Pharma, Endo, Ionis Pharma, and Amarin (PR Newswire)
17.08.17	Ionis Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
11.08.17	Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options (RTTNews)
11.08.17	Ionis to Independently Advance Inotersen and IONIS-FB-L Rx (PR Newswire)
08.08.17	Ionis Provides Improved 2017 Guidance Following Strong Financial Performance (PR Newswire)
27.07.17	Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency (PR Newswire)
26.07.17	Gainers & Losers Of July 25: FLKS, MYOK, SYRS, PCRX, RETA... (RTTNews)
25.07.17	Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast (PR Newswire)
19.07.17	Akcea Therapeutics Announces Closing of Initial Public Offering (PR Newswire)
18.07.17	Technical Reports on Drug Makers Equities -- Teva Pharma, Endo, Ionis Pharma, and Amarin (PR Newswire)
17.07.17	Ionis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration (PR Newswire)
14.07.17	Akcea Therapeutics Announces Pricing of Initial Public Offering (PR Newswire)
11.07.17	New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome (FCS) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
10.09.24		Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain
10.09.24		Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen
10.09.24		Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell
10.09.24		Freundlicher Handel: NASDAQ Composite startet im Plus
30.08.24		Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus
27.08.24		Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus
22.07.24		Freundlicher Handel in New York: NASDAQ Composite notiert zum Handelsstart im Plus

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

10.09.24

Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain

10.09.24

Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen

10.09.24

Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell

10.09.24

Freundlicher Handel: NASDAQ Composite startet im Plus

30.08.24

Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus